Otsuka says kidney disease drug preserves function in late-stage study
By Siddhi Mahatole and Sriparna Roy June 4 (Reuters) – Otsuka Pharmaceutical said on Thursday its drug in a late-stage study preserved kidney function over 12 months in patients with a type of autoimmune disease that affects the organ. Branded as Voyxact, the drug was approved in November to reduce proteinuria in patients with primary immunoglobulin A nephropathy, which causes inflammation in kidneys and can eventually lead to the organ’s […]